July 17 (Reuters) - Cassava Sciences said CEO Remi Barbier has resigned and the biotech firm named Richard Barry as interim chief executive, weeks after a medical professor linked to the company was charged with fraud.

The biotech firm's shares fell 29% to $9.56 on Wednesday.

Earlier this month, Cassava said it would form an internal committee to evaluate new probes by U.S. regulators into two senior employees.

That came days after federal prosecutors charged Hoau-Yan Wang, a doctor who collaborated with Cassava, with fraud for allegedly submitting fabricated data to the National Institutes of Health related to an experimental treatment for Alzheimer's disease.

Barbier's resignation is not due to any disagreement with the company on any matter relating to its operations, policies or practices, Cassava said on Wednesday, adding that he will receive severance compensation of $1.23 million over a period of twelve months. (Reporting by Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta)